Literature DB >> 2441996

Pharmacokinetic stochastic model with Weibull-distributed residence times of drug molecules in the body.

V K Piotrovskii.   

Abstract

The use of a function to fit blood concentration-time data points is equivalent, under certain assumptions, to specifying a model of the distribution of residence times of the drug molecules in the body (stochastic pharmacokinetic model). An empirical density function of the Weibull type is offered to describe this distribution. The model gives the following disposition function describing the time course of the drug concentrations in blood after an intravenous bolus input: C delta (t) = D/CLs lambda ts-1exp(-lambda ts). It contains only three parameters: lambda is like an 'elimination rate constant' in the single-exponential model into which the Weibull function reduces when the shape parameters becomes equal to unity; CL is the conventional systemic drug clearance, and, D is the dose injected. The Weibull function gives an analytical solution of the convolution integral for zero-order input, thereby permitting use of the model for intravenous infusion data and for extravascular administration, when the absorption may be considered to be zero-order. Using examples from the literature it is shown that in some cases the Weibull function gives a better fit than may be obtained with two- and three-exponential or gamma functions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441996     DOI: 10.1007/bf00637680

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

Review 2.  Applications of a recirculatory stochastic pharmacokinetic model: limitations of compartmental models.

Authors:  D P Vaughan; I Hope
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

3.  A linear recirculation model for drug disposition.

Authors:  D J Cutler
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

4.  Comparative pharmacokinetics of coumarin anticoagulants. IV. Application of a three-compartmental model to the analysis of the dose-dependent kinetics of bishydroxycoumarin elimination.

Authors:  R Nagashima; G Levy; R A O'Reilly
Journal:  J Pharm Sci       Date:  1968-11       Impact factor: 3.534

5.  Pharmacokinetic aspects of intravenous regional anesthesia.

Authors:  G T Tucker; R A Boas
Journal:  Anesthesiology       Date:  1971-06       Impact factor: 7.892

6.  Use of gamma distributed residence times in pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

8.  Some considerations on the estimation of steady state apparent volume of distribution and the relationships between volume terms.

Authors:  P S Collier
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

9.  Negative power functions of time in pharmacokinetics and their implications.

Authors:  M E Wise
Journal:  J Pharmacokinet Biopharm       Date:  1985-06

10.  Lignocaine kinetics in the rat.

Authors:  S Supradist; L J Notarianni; P N Bennett
Journal:  J Pharm Pharmacol       Date:  1984-04       Impact factor: 3.765

View more
  9 in total

1.  Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.

Authors:  S Appel-Dingemanse; M O Lemarechal; A Kumle; M Hubert; E Legangneux
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

2.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Systems dynamics in clinical pharmacokinetics. An introduction.

Authors:  J M van Rossum; J E de Bie
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

Review 4.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

5.  Weibull function fits to pharmacokinetic data of ribavirin in man.

Authors:  X D Liu; L Xie; K Q Han; G Q Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jul-Sep       Impact factor: 2.441

6.  The use of Weibull distribution to describe the in vivo absorption kinetics.

Authors:  V K Piotrovskii
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

7.  Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.

Authors:  M Tod; C Padoin; K Louchahi; B Moreau-Tod; O Petitjean; G Perret
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

8.  Statistics or pharmacokinetics?

Authors:  V K Piotrovskij
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

9.  Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1.

Authors:  Tobias Bonifert; Irene Gonzalez Menendez; Florian Battke; Yvonne Theurer; Matthis Synofzik; Ludger Schöls; Bernd Wissinger
Journal:  Mol Ther Nucleic Acids       Date:  2016-11-22       Impact factor: 10.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.